About the Consortium
The Haplo SCD Consortium was developed to provide resources to families, patients, and physicians pursuing Familial Haploidentical transplantation for SCD.
We have developed a consortium of seven clinical transplant sites, three processing centers, and cores in donor chimerism, anti-HLA antibodies, immunology, cell processing, biostatistics, neuroimaging, neurocognition, quality of life, pulmonary function, pulmonary vascular, radiation therapy. We've also partnered with the Children’s Sickle Cell Foundation, and the Sickle Cell Disease Association of Illinois (SCDAI) to help educate patients and their families regarding sickle cell disease and familial haploidentical stem cell transplant.
The Collaborating Centers have joined efforts on the protocol The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812).
Please contact Principal Investigator Mitchell Cairo, MD for additional information or any of the seven clinical transplant sites to refer patients.
The Haplo SCD Consortium was developed to provide resources to families, patients, and physicians pursuing Familial Haploidentical transplantation for SCD.
We have developed a consortium of seven clinical transplant sites, three processing centers, and cores in donor chimerism, anti-HLA antibodies, immunology, cell processing, biostatistics, neuroimaging, neurocognition, quality of life, pulmonary function, pulmonary vascular, radiation therapy. We've also partnered with the Children’s Sickle Cell Foundation, and the Sickle Cell Disease Association of Illinois (SCDAI) to help educate patients and their families regarding sickle cell disease and familial haploidentical stem cell transplant.
The Collaborating Centers have joined efforts on the protocol The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812).
Please contact Principal Investigator Mitchell Cairo, MD for additional information or any of the seven clinical transplant sites to refer patients.
